37 posts tagged sirtris

Just a lil' bit about me... I am 32 years old and for the past 12 years have focused on building my business and enjoying my time with my wife. Unfortunately, I did not focus too much on my healthy well being. Throughout my teens and up until I was about 20 I was very physically active.

Just a lil' bit about me... I am 32 years old and for the past 12 years have focused on building my business and enjoying my time with my wife. Unfortunately, I did not focus too much on my healthy well being. Throughout my teens and up until I was about 20 I was very physically active.

Glaxo is playing hardball with Massachusetts. Chris Viehbacher, who heads the drugmaker’s North American pharma biz, sent what The Boston Herald calls “harshly worded letters” to three state politicans to accuse the state of a “strong anti-biopharmaceutical streak” and complains of attempts to “attack

Just a lil' bit about me... I am 32 years old and for the past 12 years have focused on building my business and enjoying my time with my wife. Unfortunately, I did not focus too much on my healthy well being. Throughout my teens and up until I was about 20 I was very physically active.

Back in December, my friend Steve Sjuggerud described a British spending spree taking place in America. At the time, the pound was worth about $1.95, and Brits were enjoying a 50% discount on their Christmas shopping across the pond.

Back in December, my friend Steve Sjuggerud described a British spending spree taking place in America. (more…) Related ArticlesHow to Sell What Big Pharma Will Pay Any Price to BuyGlobal Investing Roundups Wednesday, April 16th, 2008Your Next Car Made in China?Things are Getting Really Bad, Latte

For the first time in almost 10 months, and not surprisingly, coming on the heels of the GSK / Sirtris buyout that occurred last week, Elixir Pharmaceuticals has announced that they have been granted a patent for a class of SIRT2 regulators.

Tired of Sirtris-GSK talk yet? Too bad. As we now bring you, the venture angle. As you no doubt know by now, GlaxoSmithKline will pay $725 million for Sirtris Pharmaceuticals Inc., paying $22.50 per share, an 84% premium over Sirtris' closing price. We've already gone over the particulars of the deal, including some of our concerns.

There were lots of reasons to evoke the color green this week. Lest you've forgotten, Tuesday was Earth Day. The IN VIVO Blog team hopes you celebrated appropriately--perhaps by replacing those incandescent light bulbs with compact fluorescent ones or off-setting the carbon dioxide emissions from a recent plane trip.

Drug giant GlaxoSmithKline plc will buy clinical-stage biotech Sirtris Pharmaceuticals Inc. for $720 million. GlaxoSmithKline plc's legal counsel include Victor Lewkow, Arthur Kohn and Lillian Raben...